Actively Recruiting
TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients
Led by Dana-Farber Cancer Institute · Updated on 2026-04-23
270
Participants Needed
3
Research Sites
202 weeks
Total Duration
On this page
Sponsors
D
Dana-Farber Cancer Institute
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research is being done to assess whether an exercise intervention with protein intake support vs a health education and support program will make it easier for women age 65 or older who are receiving chemotherapy for breast cancer to receive all of their planned chemotherapy according to schedule and at the planned dose.
CONDITIONS
Official Title
TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women age 65
- Diagnosed with stage I-III invasive breast cancer
- BMI between 18-50 kg/m2
- Scheduled to begin at least 10 weeks of neoadjuvant or adjuvant cytotoxic chemotherapy for curative intent
- Eligible if enrolled in chemotherapy drug trial with anthracycline or taxane regimen, unless doses change based on response
- Self-reported ability to walk for 6 minutes and/or 2 blocks (with or without assistive device)
- Ability to provide written informed consent
- Ability to understand, speak, and read English
You will not qualify if you...
- Following therapeutic diet contraindicated for THRIVE-65 diet
- Engaging in 2 or more strength training sessions per week for at least 3 consecutive months in past year
- Engaging in competitive aerobic events (e.g., marathon, triathlon) in past year
- Medical conditions or medications preventing exercise participation
- Current use of weight-loss medication
- History of alcohol or substance abuse within past 12 months
- History of dementia
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
2
Case Western Reserve University/University Hospitals Cleveland
Cleveland, Ohio, United States, 44106
Actively Recruiting
3
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15232
Actively Recruiting
Research Team
K
Kathryn Schmitz, PhD, MPH
CONTACT
J
Jennifer Ligibel, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here